What does the evidence say about Arabinoxylan Gut Microbiota Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Arabinoxylan Gut Microbiota Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Results RS2 and AX reduced body weight, improved insulin sensitivity (lower HOMA-IR, p Conclusion RS2 and AX alleviated PCOS phenotypes by enriching Ligilactobacillus, increasing SCFA production, and activating hepatic AMPK signaling. [Liang Y (2025); evidence level 4] - Background Polycystic ovary syndrome (PCOS) is linked to hyperandrogenism and gut microbiota dysbiosis. [Liang Y (2025); evidence level 4] - Dietary fibers (DFs), such as resistant starch type 2 (RS2) and arabinoxylan (AX), modulate the gut microbiota and produce short-chain fatty acid (SCFA), potentially ameliorating PCOS symptoms. [Liang Y (2025); evidence level 4] - By replacing arabinoxylan in high proportion, we reduced the GI value of bread and added high purity arabinoxylan to the bread as a basic low GI recipe to improve the textural and other characteristics of the bread. [Bai Z (2025); evidence level 4] - We found that when the proportion of pure WUAX was 0.5 %, the bread quality was improved, mainly in terms of hardness, springiness, moisture distribution, microstructure and crystallinity. [Bai Z (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.